Mirum Pharmaceuticals (MIRM) EBITDA Margin (2021 - 2026)
Mirum Pharmaceuticals' (MIRM) quarterly EBITDA Margin came in at 493.78% in Q1 2026, down 48017.0% year-on-year from N/an in Q1 2025, and down 16002.39% quarter-over-quarter from 3.07% in Q4 2025.
Mirum Pharmaceuticals (MIRM) EBITDA Margin (2021 - 2026) Analysis & Trends
Mirum Pharmaceuticals' EBITDA Margin history runs 6 years deep, the most recent figure standing at 493.78% for Q1 2026.
- On a quarterly basis, EBITDA Margin fell 48017.0% year-over-year to 493.78% in Q1 2026; TTM through Mar 2026 was 139.82%, a 11969.0% decrease from a year earlier, with the FY2025 full-year figure at 4.25%, up 2176.0% from the prior year.
- EBITDA Margin fell to 493.78% in Q1 2026 per MIRM's latest filing, from 3.07% in the prior quarter.
- Across five years, EBITDA Margin topped out at 1.96% in Q3 2025 and bottomed at 493.78% in Q1 2026.
- The 5-year median for EBITDA Margin is 46.85% (2023), against an average of 94.21%.
- Across the five-year window, EBITDA Margin surged 132994 bps in 2022 and slumped 48017 bps in 2026, its largest moves.
- Year by year, EBITDA Margin stood at 122.41% in 2022, then jumped by 62 bps to 46.85% in 2023, then soared by 48 bps to 24.36% in 2024, then soared by 87 bps to 3.07% in 2025, then plunged by 16002 bps to 493.78% in 2026.
- Per Business Quant, the three latest MIRM EBITDA Margin figures stand at 493.78% (Q1 2026), 3.07% (Q4 2025), and 1.96% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Mirum Pharmaceuticals | 6.73 Bn | 6.34 Bn | 131.08 Mn | -493.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -493.78% |
| Dec 31, 2025 | -3.07% |
| Sep 30, 2025 | 1.96% |
| Jun 30, 2025 | -3.90% |
| Mar 31, 2025 | -13.61% |
| Dec 31, 2024 | -24.36% |
| Sep 30, 2024 | -14.03% |
| Jun 30, 2024 | -31.12% |
| Mar 31, 2024 | -38.24% |
| Dec 31, 2023 | -46.85% |
| Sep 30, 2023 | -52.69% |
| Jun 30, 2023 | -64.73% |
| Mar 31, 2023 | -85.92% |
| Dec 31, 2022 | -122.41% |
| Sep 30, 2022 | -175.09% |
| Jun 30, 2022 | -179.83% |
| Mar 31, 2022 | -253.92% |
| Dec 31, 2021 | -1,452.36% |
| Sep 30, 2021 | -856.48% |
| Jun 30, 2021 | -340.01% |